2019/12/03

Ina Research Co., Ltd. (hereinafter “the Company”) has decided today to enter into an agency contract with SAGE HEALTHCARE PTE LTD (hereinafter “SAGE”) in Singapore for the purpose of expanding sales of non-clinical studies focusing on pharmaceuticals. Information about entering into an agency contract with SAGE HEALTHCARE PTE LTD. – PDF (132KB)

2019/09/06

Ina Research Inc. (hereinafter referred to as “our company”) is pleased to announce that our company has decided to start the agency business for ViruSure (Austria : hereinafter referred to as “VS”), which is a contract research organization (hereinafter referred to as “CRO” ) in Japan and Taiwan today. (Please refer to the below PDF file for more details.) Announcement concerning the start of agency business with ViruSure GmbH (PDF: 128KB)

2019/08/07

Ina Research Inc. (INA) is pleased to announce the signing of an agency agreement with Level Biotechnology Inc. (LBI), a Taiwanese Contract Research Organization. 1.Market Potential The biopharmaceutical industry in Taiwan is currently growing at an unprecedented rate. With LBI as our locally-based agent, Taiwanese customers can now access INAs services in nonhuman primates, studies which are required as part of the biopharmaceutical development process. In this way, INA hopes to establish a mutually-complementary relationship with LBI, and make inroads into this growing market. 2. About LBI (1) Company Name: Level Biotechnology Inc. (2) Address: No. 80, Lane 169, Kangning St., His-Chih Dist., New Taipei City 221, Taiwan R.O.C. (3)

2019/07/08

A column regarding to the Grobal SEND Alliance (G-SEND) was posted on the website of Tokyo University AMED iD3 Catalyst Unit. G-SEND is a non-profit consortium, consisting of CROs from Japan, South Korea, Taiwan, Singapore, the US and Switzerland. They provide SEND data sets which are created in a standardized process and Ina Reseach is the central CRO as their base. Please see the link below for the article: http://www.id3catalyst.jp/e/column03.html